CH5132799
10mM in DMSO
- Product Code: 157667
CAS:
1007207-67-1
| Molecular Weight: | 377.43 g./mol | Molecular Formula: | C₁₅H₁₉N₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD22419020 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
CH5132799 is an investigational anti-cancer agent primarily studied for its potential in treating hematologic malignancies, particularly acute myeloid leukemia (AML). It functions as a menin-MLL (mixed lineage leukemia) interaction inhibitor, disrupting the binding between the menin protein and MLL fusion proteins or mutant forms that drive leukemogenesis. By inhibiting this protein-protein interaction, CH5132799 suppresses the expression of key oncogenes such as HOXA9 and MEIS1, which are critical for the proliferation and survival of leukemia cells.
The compound has shown potent anti-leukemic activity in preclinical models, including cell line studies and animal models bearing MLL-rearranged or NPM1-mutated AML. It induces differentiation of leukemic blasts and promotes apoptosis, leading to reduced tumor burden. Due to its targeted mechanism, CH5132799 holds promise for patients with genetically defined subtypes of AML who have limited treatment options.
Clinical development has focused on evaluating its safety, pharmacokinetics, and efficacy in early-phase trials. Its application is centered on targeted therapy approaches in oncology, aiming to provide a precision medicine option for AML patients with specific molecular abnormalities.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿13,950.00 |
+
-
|
CH5132799
CH5132799 is an investigational anti-cancer agent primarily studied for its potential in treating hematologic malignancies, particularly acute myeloid leukemia (AML). It functions as a menin-MLL (mixed lineage leukemia) interaction inhibitor, disrupting the binding between the menin protein and MLL fusion proteins or mutant forms that drive leukemogenesis. By inhibiting this protein-protein interaction, CH5132799 suppresses the expression of key oncogenes such as HOXA9 and MEIS1, which are critical for the proliferation and survival of leukemia cells.
The compound has shown potent anti-leukemic activity in preclinical models, including cell line studies and animal models bearing MLL-rearranged or NPM1-mutated AML. It induces differentiation of leukemic blasts and promotes apoptosis, leading to reduced tumor burden. Due to its targeted mechanism, CH5132799 holds promise for patients with genetically defined subtypes of AML who have limited treatment options.
Clinical development has focused on evaluating its safety, pharmacokinetics, and efficacy in early-phase trials. Its application is centered on targeted therapy approaches in oncology, aiming to provide a precision medicine option for AML patients with specific molecular abnormalities.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :